Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine […]

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence

Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1

Myriad Genetics announced enhancements to the GeneSight® Psychotropic test.

ComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers. This comprehensive model is expected to identify more patients that could benefit from a change in their breast care.

Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response